NCT03102593 - A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

April 9, 2019

Study Completion Date

April 9, 2019

Conditions

Primary Immune Thrombocytopenia

Interventions

DRUG

ARGX-113

ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly

OTHER

Placebo

ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly

Trial Locations (30)

Unknown

Vienna, Vienna

Wien, Vienna

Leuven, Leuven

Mont-Godinne, Namur

Brno, Brno

Praha, Prague

Bordeaux, Bordeaux

Grenoble, Grenoble

Paris, Paris

Berlin, Berlin

Hanover, Hanover

Tubingen, Tübingen

Budapest, Budapest

Debrecen, Debrecen

Gyula, Gyula

Kaposvar, Kaposvár

Nyiregyhaza, Nyíregyháza

Pecs, Pécs

Lublin, Lublin

Opole, Opole

Wroclaw, Wroclaw

A Coruna, A Coruña

Barcelona, Barcelona

Madrid, Madrid

Valencia, Valencia

Dnipro, Dnipro

Ivano-Frankivsk, Ivano-Frankivsk

Nikolaev, Mykolayiv

Uzhgorod, Uzhhorod

London, London